Overview

Neurodexis11 is a biotechnology company developing first-in-class HDAC11 inhibitors to treat Alzheimer’s disease and other CNS disorders. Our lead candidate, PB151, is a selective, brain-penetrant, and orally bioavailable compound that targets neuroinflammation and gene regulation — mechanisms not addressed by current therapies . Backed by strong translational data in Alzheimer’s models and human cells, we are advancing toward IND-enabling studies with the goal of delivering an accessible, disease-modifying therapy. Operating at the intersection of neuroscience, epigenetics, and drug development, Neurodexis11 is positioned within the rapidly growing neurotherapeutics industry.